<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176851</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0915-PR-0031</org_study_id>
    <nct_id>NCT01176851</nct_id>
  </id_info>
  <brief_title>Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers</brief_title>
  <acronym>Gly1</acronym>
  <official_title>Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics, the absolute
      bioavailability and the lung bioavailability of inhaled Glyco pMDI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine pharmacokinetics of glycopyrrolate</measure>
    <time_frame>over 24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters</measure>
    <time_frame>over 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular parameters</measure>
    <time_frame>over 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry and haematology, urinalysis</measure>
    <time_frame>over 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>during the whole study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glyco pMDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glyco pMDI 100 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco pMDI Charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glyco pMDI 100 µg + charcoal block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco IV injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glyco solution for injection 100 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Single administration of Glyco pMDI 100 µg</description>
    <arm_group_label>Glyco pMDI</arm_group_label>
    <other_name>CHF 5259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Single administration of Glyco pMDI 100 µg after charcoal ingestion</description>
    <arm_group_label>Glyco pMDI Charcoal</arm_group_label>
    <other_name>CHF 5259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Single intravenous injection of glycopyrrolate 100 µg</description>
    <arm_group_label>Glyco IV injection</arm_group_label>
    <other_name>Robinul Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females healthy volunteers aged 18-65 years;

          2. Written informed consent obtained before the first trial related activity.

          3. Able to understand the study procedures, the risks involved and ability to be trained
             to use the devices correctly.

          4. Body Mass Index (BMI) between 18.0 and 32.0 kg/m2;

          5. Non- or ex-smokers who smoked &lt; 5 pack years;

          6. Good physical and mental status;

          7. Normal blood pressure and heart rate;

          8. Electrocardiogram (ECG)considered as normal;

          9. Results of laboratory tests within the normal ranges.

         10. Lung function measurements within the normal ranges.

        Exclusion Criteria:

          1. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before
             inhalation of the study medication;

          2. Pregnant or lactating women or women of childbearing potential, UNLESS they are using
             one or more of the acceptable methods of contraception. Male subjects not willing to
             use an acceptable method of contraception.

          3. Positive HIV1 or HIV2 serology;

          4. Positive results from the Hepatitis serology which indicates acute or chronic
             Hepatitis B or Hepatitis C;

          5. Unsuitable veins for repeated venipuncture;

          6. History of substance abuse or drug abuse within 12 months prior to screening visit or
             with a positive urine drug screen at screening;

          7. Clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical investigation;

          8. Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal,
             endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with
             successful completion of this protocol;

          9. Participation in another clinical trial less than 8 weeks prior to inhalation of the
             study medication; participation in another clinical trial using radioactive material
             within 1 calendar year;

         10. History of hypersensitivity to M3 Antagonists or any of the excipients contained in
             any of the formulations used in the trial;

         11. Any drug treatment, including prescribed or OTC medicines as well as vitamins,
             homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or
             enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) preceding the
             first intake of the study drug, with the exception of occasional paracetamol (maximum
             2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions).

         12. Treatment within the previous 3 months with any drug known to have a well defined
             potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).

         13. Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages
             or grapefruit containing foods or beverages from 48 hour prior to the first intake of
             study medication and for the entire duration of the study.

         14. Heavy caffeine drinker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Martine Cartier, Head of Clinical Operations</name_title>
    <organization>Chiesi Farmaceutici SpA</organization>
  </responsible_party>
  <keyword>None (study in healthy volunteers)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

